临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1970972-74-7

Danicamtiv (MYK-491)

CAS号:1970972-74-7
分子式: C16H20F3N5O4S 分子量: 435.42
产品形式: Free Base
研发状态: Completed
研发用途: Heart Failure With Reduced Ejection Fraction; Dilated Cardiomyopathy
研究机构: Bristol-Myers Squibb
研发日期: February 6 2018
研发阶段: Phase 1 : Phase 2
Danicamtiv (MYK-491, SAR 440181) is a novel cardiac myosin activator that enhances cardiomyocyte contraction.

CAS: 19685-09-7

(S)-10-Hydroxycamptothecin

中文名称: (S)-10-羟基喜树碱
CAS号:19685-09-7
分子式: C20H16N2O5 分子量: 364.35
产品形式: free base
研发状态: Recruiting
研发用途: Advanced Solid Tumor
研究机构: TaiRx Inc.
研发日期: October 31 2023
研发阶段: Phase 1
(S)-10-Hydroxycamptothecin (10-HCPT) is a DNA topoisomerase I inhibitor with potent anti-tumor activity.

CAS: 196597-26-9

Ramelteon

中文名称: 雷美替胺
CAS号:196597-26-9
分子式: C16H21NO2 分子量: 259.34
产品形式: free base
研发状态: Completed
研发用途: Delirium
研究机构: Rhode Island Hospital
研发日期: May 9 2019
研发阶段: Phase 4
Ramelteon (TAK-375) is a novel melatonin receptor agonist for human MT1 and MT2 receptors and chick forebrain melatonin receptors with Ki of 14 pM, 112 pM and 23.1 pM, respectively.

CAS: 19608-29-8

Clascoterone

中文名称:21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮
CAS号:19608-29-8
分子式: C24H34O5 分子量: 402.52
产品形式: free base
研发状态: Completed
研发用途: Healthy Volunteers
研究机构: Cassiopea SpA
研发日期: June 6 2018
研发阶段: Phase 1
Clascoterone (Winlevi, Cortexolone 17 alpha-propionate, Cortexolone 17α-propionate, CB-03-01) is a topical and peripherally selective antagonist of androgen receptor (AR).

CAS: 195514-63-7

Rimiducid (AP1903)

中文名称:利米多赛
CAS号:195514-63-7
分子式: C78H98N4O20 分子量: 1411.63
产品形式: Free base
研发状态: Recruiting
研发用途: Brain Tumor Pediatric; Medulloblastoma Childhood; Embryonal Tumor; High Grade Glioma; Diffuse Midline Glioma; Diffuse Intrinsic Pontine Glioma; Brain Tumor Adult
研究机构: Bambino Gesù Hospital and Research Institute
研发日期: November 9 2023
研发阶段: Phase 1
Rimiducid (AP1903) is a chemical protein dimerizer and binds tightly to the target FKBP fusion protein while binding minimally to the abundant natural FKBP. Rimiducid elicites potent and dose-dependent apoptosis of cells in culture expressing dimerizer-dependent Fas constructs, with an EC50 of ≈0.1 nM.

CAS: 1952251-28-3

TAK-659

CAS号:1952251-28-3
分子式: C17H21FN6.HCl 分子量: 380.85
产品形式: hydrochloride
研发状态: Withdrawn
研发用途: Lymphoma Non-Hodgkin
研究机构: Calithera Biosciences Inc; Nektar Therapeutics
研发日期: April 3 2019
研发阶段: Phase 1
TAK-659 is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM. It is selective against most other kinases, but potent toward both SYK and FLT3.